Search Page

The search found 2 results in 0.015 seconds.

Search results

1. Breast Cancer: HER2 (ERBB2) targeting therapies

   HER2 (encoded by the ERBB2 gene) is a tyrosine kinase that is one of the receptors for EGF (epidermal growth factor). HER2 is often mutated in tumors (approximately one quarter of breast cancers, for example), and mutant HER2's dysregulated activity drives several pathways that promote cancer cell phenotypes. Among the most studied downstream pathways that are activated by EGF are the MAPK and PI3K/Akt pathways. Mutations in the HER2 protein (referred to has HER2v here) are associated with poor prognosis. There are essentially two approaches for targeting HER2v positive cancers

   efaccena - 11/04/2023 - 2:44pm

2. Therapy optimization

   Patients with a given disease may differ dramatically in the desired and undesired effects of one and the same standard drug therapy. Extreme examples are:

   efaccena - 24/03/2016 - 9:43am